Iliad Biotechnologies

Developer of immunity-inducing vaccine for the prevention and treatment of pertussis

placeNew York City, New York, United States calendar_todayFounded 2012 groups8 employees language iliadbio.com

Social engagement

Social engagement: 2K social following, 8 posts in the last 12 months — below the industry typical range.

Investor mix

8 investors on record; lead investors include Livent, Knottpartners, RA Capital Management.

Investor typeCountShare
Venture capital225%
Other / undisclosed675%

Recent activity

22 Apr 2026
Partnership
hVIVO
25 Mar 2026
Event
World Vaccine Congress Washington 2026
Coming soon